Cooley

Lauren Leonard

Associate



lleonard@cooley.com

+1 617 937 1381

Boston

Life Sciences Corporate Partnering and Licensing
Life Sciences and Healthcare Regulatory
Emerging Companies
Venture Capital
Technology
Digital Health
Mergers and Acquisitions
Capital Markets
Biotechnology

Lauren is a corporate attorney who provides strategic counsel to public and private life sciences and technology companies throughout their life cycle. Lauren's practice focuses on life sciences partnering transactions, including licensing arrangements, strategic collaborations and alliances, technology acquisitions and development, services, distribution, manufacturing, supply, clinical trial and other commercial agreements. Lauren regularly advises companies at all stages of growth regarding intellectual property-related issues and other general corporate matters, including formation and corporate governance, protection of intellectual property, financing and contract negotiations.

Lauren's recent representative matters:

- A multinational pharmaceutical company in its $5.3 billion exclusive worldwide collaboration and license agreement with a biotechnology company to co-develop and co-commercialize a foundational therapy for overweight and obesity patients*
- An antibody services and technology provider in library development agreements with various partners and in its acquisition by a global provider of life sciences service solutions*
- A biotechnology company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring in its exclusive worldwide license and collaboration agreement with a multinational pharmaceutical company for the development of a radiotherapeutic candidate for cancer*
- A clinical-stage genetic medicine company in its global research collaboration focused on discovering and developing in vivo gene-editing therapy for liver disease*
- A clinical-stage revenue-generating global antibody engineering company in the sale of its radiopharmaceutical business to a global commercial-stage biopharmaceutical company*
- A public biopharmaceutical company in its $1 billion exclusive license agreement with a global pharmaceutical and healthcare company for an oral non-incretin development candidate in obesity and associated metabolic disorders*
- A biopharmaceutical company in the acquisition of its emerging gene therapies for inherited retinal diseases by a clinical-stage gene therapy company*

* Representation handled before joining Cooley

Education

Boston University School of Law JD, summa cum laude, senior editor for Boston University Law Review, Edward F. Hennessey Scholar, Paul J. Liacos Distinguished Scholar, Joseph Tauro Distinguished Scholar, Alumni Academic Achievement Award, 2019

University at Buffalo Honors College BS, Biomedical Engineering, summa cum laude, 2016

Admissions & Credentials

Massachusetts

Rankings & Accolades

LMG Life Sciences: US Rising Star – Financial and Corporate (2025)

Best Lawyers in America: Ones to Watch for corporate law (2025, 2026) technology law and securities/capital market law (2026)